Mandate

Vinge advises CMA Microdialysis in connection with the sale of pre-clinical business

July 04, 2011

Vinge has advised CMA Microdialysis in connection with the sale of its pre-clinical business to Harvard Biosciences. The main shareholders of MCA Microdialysis are Investor Growth Capital and Bure Equity. In connection with the transaction, the company has changed its name to Dipylon Medical.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, fellow partner Fredrik Dahl and associate Claes Henriksson.

Related

Vinge advises Wihlborgs Fastigheter in connection with the financing of property acquisition valued at SEK 13.3 billion

Vinge advises Wihlborgs Fastigheter AB (publ) in connection with the financing of the acquisition of all of Castellum’s property holdings in Malmö, Lund and Helsingborg. The financing has been secured through Danske Bank, SEB and Swedbank.
June 29, 2026

Vinge advises Ambea on the public offer for Humana

Ambea AB (publ) has made a public offer for all shares in Humana AB. The offer values all shares in Humana at approximately SEK 2,96 billion. The consideration consists of a mix of shares, cash and a CVR (contingent value right).
June 29, 2026

Vinge has advised Gamma Waves on Sportway’s EUR 20 million financing round

Vinge has acted as legal adviser to Gamma Waves in connection with Sportway’s EUR 20 million financing round. The round was led by Gamma Waves, together with continued participation from existing shareholders, and values Sportway at approximately EUR 92 million (around SEK 1 billion) post-money.
June 24, 2026